JP2015514716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514716A5 JP2015514716A5 JP2015503652A JP2015503652A JP2015514716A5 JP 2015514716 A5 JP2015514716 A5 JP 2015514716A5 JP 2015503652 A JP2015503652 A JP 2015503652A JP 2015503652 A JP2015503652 A JP 2015503652A JP 2015514716 A5 JP2015514716 A5 JP 2015514716A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- fragment
- sample
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618489P | 2012-03-30 | 2012-03-30 | |
| US61/618,489 | 2012-03-30 | ||
| PCT/US2013/034646 WO2013149171A2 (en) | 2012-03-30 | 2013-03-29 | Methods for increasing efficacy of cd37-based therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514716A JP2015514716A (ja) | 2015-05-21 |
| JP2015514716A5 true JP2015514716A5 (enExample) | 2016-04-28 |
Family
ID=49261399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503652A Withdrawn JP2015514716A (ja) | 2012-03-30 | 2013-03-29 | Ｃｄ３７に基づく治療の有効性を増大させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150093397A1 (enExample) |
| EP (1) | EP2831585A4 (enExample) |
| JP (1) | JP2015514716A (enExample) |
| KR (1) | KR20140143810A (enExample) |
| CN (1) | CN104364651A (enExample) |
| AU (1) | AU2013237826A1 (enExample) |
| BR (1) | BR112014024487A2 (enExample) |
| CA (1) | CA2868049A1 (enExample) |
| HK (1) | HK1202156A1 (enExample) |
| IL (1) | IL234813A0 (enExample) |
| MX (1) | MX2014011745A (enExample) |
| RU (1) | RU2014140119A (enExample) |
| SG (1) | SG11201405766SA (enExample) |
| WO (1) | WO2013149171A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX338932B (es) | 2010-03-12 | 2016-05-06 | Immunogen Inc | Moleculas de union cd37 y sus inmunoconjugados. |
| CN105999293B (zh) | 2011-04-01 | 2019-07-23 | 德彪发姆国际有限公司 | Cd37结合分子及其免疫缀合物 |
| WO2015175533A2 (en) * | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| UA125496C2 (uk) | 2015-06-08 | 2022-04-13 | Дебіофарм Інтернаціонал, С.А. | Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20 |
| AU2016316758B2 (en) * | 2015-08-28 | 2023-02-02 | Debiopharm International, S.A. | Antibodies and assays for detection of CD37 |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| CN107603276A (zh) * | 2017-09-14 | 2018-01-19 | 郑州乐业生物科技有限公司 | 一种稳定的生物染色剂及其制备方法 |
| CN110511900B (zh) * | 2018-05-21 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 精子细胞表面标志物的筛选与应用 |
| CA3101790A1 (en) | 2018-05-30 | 2019-12-05 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate dosing regimens |
| JPWO2021241061A1 (enExample) * | 2020-05-29 | 2021-12-02 | ||
| CN111579798A (zh) * | 2020-05-29 | 2020-08-25 | 深圳市锦欣医疗科技创新中心有限公司 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
| RU2767693C1 (ru) * | 2021-03-03 | 2022-03-18 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ морфометрической оценки прогноза течения диффузной B-крупноклеточной лимфомы по индексу доли опухолевых клеток, экспрессирующих pSTAT3 и pAKT1 в лимфатических узлах |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318906B2 (en) * | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2009085576A2 (en) * | 2007-12-28 | 2009-07-09 | Spring Bioscience Corporation | Positive control cell pellets for immunohistochemistry and methods of use thereof |
| PT2132228E (pt) * | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| WO2010057047A1 (en) * | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| MX338932B (es) * | 2010-03-12 | 2016-05-06 | Immunogen Inc | Moleculas de union cd37 y sus inmunoconjugados. |
| AU2011239583A1 (en) * | 2010-04-15 | 2012-11-29 | Alper Biotech, Llc | Monoclonal antibodies against HER2 antigens, and uses therefor |
-
2013
- 2013-03-29 RU RU2014140119A patent/RU2014140119A/ru not_active Application Discontinuation
- 2013-03-29 EP EP13770074.6A patent/EP2831585A4/en not_active Withdrawn
- 2013-03-29 AU AU2013237826A patent/AU2013237826A1/en not_active Abandoned
- 2013-03-29 BR BR112014024487A patent/BR112014024487A2/pt not_active IP Right Cessation
- 2013-03-29 SG SG11201405766SA patent/SG11201405766SA/en unknown
- 2013-03-29 CA CA2868049A patent/CA2868049A1/en not_active Abandoned
- 2013-03-29 CN CN201380018486.5A patent/CN104364651A/zh active Pending
- 2013-03-29 WO PCT/US2013/034646 patent/WO2013149171A2/en not_active Ceased
- 2013-03-29 JP JP2015503652A patent/JP2015514716A/ja not_active Withdrawn
- 2013-03-29 KR KR1020147030199A patent/KR20140143810A/ko not_active Withdrawn
- 2013-03-29 US US14/389,727 patent/US20150093397A1/en not_active Abandoned
- 2013-03-29 HK HK15102580.5A patent/HK1202156A1/xx unknown
- 2013-03-29 MX MX2014011745A patent/MX2014011745A/es unknown
-
2014
- 2014-09-23 IL IL234813A patent/IL234813A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kinneer et al. | SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads | |
| Schuster et al. | Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas | |
| Saadeh et al. | EGFR as a clinical marker in glioblastomas and other gliomas | |
| Lok et al. | PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer | |
| KR101982317B1 (ko) | Folr1 암 치료의 효능을 증가시키기 위한 방법 | |
| Zhou et al. | Neddylation inhibition upregulates PD‐L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma | |
| Vecchione et al. | A vulnerability of a subset of colon cancers with potential clinical utility | |
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| Salles et al. | Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma | |
| L'Italien et al. | Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies | |
| Yaromina et al. | Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability | |
| Zhang et al. | A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia | |
| Wilkinson et al. | Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation | |
| US20180105882A1 (en) | New biomarker for outcome in aml | |
| Genzen et al. | Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. | |
| Yang et al. | Immunohistochemical detection of poly (ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas | |
| Cheng et al. | Advances in personalized treatment and prognostic factors of follicular lymphoma | |
| Takata et al. | Identification of TRA‐1‐60‐positive cells as a potent refractory population in follicular lymphomas | |
| Riedell et al. | Should we use cell of origin and dual-protein expression in treating DLBCL? | |
| Bouley et al. | Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss | |
| Zhou et al. | LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair | |
| Duchatel et al. | Dipg-03. Targeting pi3k using the blood brain barrier penetrable inhibitor, gdc-0084, for the treatment of diffuse intrinsic pontine glioma (dipg) | |
| Kourelis et al. | A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma | |
| Ali et al. | PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling | |
| Balakrishnan et al. | Targeting Diffuse Midline Glioma with a novel anti-CD99 Antibody |